A 12% Secured Loan Says More About Forward Water Than Its Clean-Water Pitch

A tiny Canadian company just announced it closed a $535,000 financing. Small number, and it reads like momentum at first — but read the actual terms and that press release becomes the most candid description of Forward Water Technologies you will find anywhere.

Here is what got issued. Not equity in the growth story the company sells, but a secured bridge debenture that pays 12% interest a year, matures in 36 months, and is backed by a first-priority security interest in all of the company's present and future property. On top of the interest, lenders get a fee equal to 10% of their money when it's repaid, plus 8,000 warrants for every $1,000 lent. And $225,000 of the $535,000 — about 42 cents of every dollar — came from the company's own insiders.

When a business has to raise money at 12%, secured against everything it owns, with a double-digit exit fee and its own board members supplying nearly half the cash, the debt market is not stamping the equity story as strong. It is telling you the plumbing is tight.

Fairness first: the underlying pitch is real. Forward Water commercializes forward osmosis, a membrane process that pulls clean water out of wastewater and lets an industrial user reclaim a large share of the water it would otherwise discard. Water scarcity is a legitimate secular theme, and a company that does it well could matter. None of that is the problem.

The problem is the scale of the economics the loan exposes. For the fiscal year ended March 31, 2026, the company reported revenue of about $91,600 — a working prototype, not a commercial engine — against a net loss of roughly $2.65 million. That loss works out to about $0.053 per share on roughly 50 million weighted-average shares, which at a share price around $0.04 puts the entire company at a market value of about $2 million. Step back and sit with that for a second: a single year's losses are bigger than the market's value for the whole business.

That same loss also reveals how little the fresh raise actually buys. On March 31 the company had about $349,000 of cash, and it burned roughly $1.24 million through operations over the trailing twelve months. Set the $535,000 against a burn rate like that and the bridge funds a few months of runway — months during which it also owes annual interest on the new debt, carries roughly $800,000 of convertible debentures and a quarter-million-dollar loan already on its books, and faces the 10% fee plus a likely bigger equity raise this side of July 2027, because that is exactly what the debenture's terms are designed to force.

The structure is worth spelling out, because it is the tell. The debenture gives holders a "repayment right" triggered if the company raises at least $1 million before July 1, 2027: they can demand their money back, or roll it into that future raise. What you're watching is bridge financing to get to a bigger financing. The 12% secured loan is not how you fund a company that has arrived; it is how you fund a company that needs to make it to the next door without running out of cash on the way.

None of this is a verdict on forward osmosis as a technology, and I won't pretend to know the outcome. But the defining feature of the equity here is that the financing mechanics outrank the sales pitch. If the clean-water story were priced the way it is told, the company wouldn't be borrowing dollars at 12% against a lien on everything it owns. When the cost of capital is that steep, the market is telling you the risk it sees in the ordinary course — and that, not the brochure, is the honest number to weigh against any future check you might write into a dilution-heavy raise.